Solventum Corporation/$SOLV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Solventum Corporation
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.
- Ticker
- $SOLV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 20,584
- Headquarters
- Eagan, United States
- Website
- www.solventum.com
SOLV Metrics
BasicAdvanced
$15B
100.39
$0.90
0.75
-
Price and volume
Market cap
$15B
Beta
0.75
52-week high
$94.16
52-week low
$62.38
Average daily volume
1.2M
Financial strength
Current ratio
1.033
Quick ratio
0.515
Long term debt to equity
0.992
Total debt to equity
1.098
Interest coverage (TTM)
2.10%
Profitability
EBITDA (TTM)
1,036
Gross margin (TTM)
55.13%
Net profit margin (TTM)
1.91%
Operating margin (TTM)
6.31%
Effective tax rate (TTM)
8.24%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
2.29%
Return on equity (TTM)
3.19%
Valuation
Price to earnings (TTM)
100.392
Price to revenue (TTM)
1.916
Price to book
3.2
Price to tangible book (TTM)
-4.91
Growth
Revenue change (TTM)
-2.86%
Earnings per share change (TTM)
-89.67%
3-year revenue growth (CAGR)
-0.02%
3-year earnings per share growth (CAGR)
-51.71%
What the Analysts think about SOLV
Analyst ratings (Buy, Hold, Sell) for Solventum Corporation stock.
Analyst projections of the future price of Solventum Corporation stock.
Bulls say / Bears say
Solventum raised its 2026 adjusted EPS outlook to $7.20–$7.30 and expects organic growth towards the top of its 2.5%–3.0% range. Management says growth would be close to 4% excluding SKU exits and the temporary ERP order reversal, and the largest ERP cutover is complete. (Solventum)
Adjusted operating margin improved by 210 basis points year on year to 22.8% in the first nine months. Solventum also expects its four-year efficiency programme to deliver about $500 million in annual savings, giving it scope to keep improving profitability. (Solventum)
Third-quarter organic sales fell 2.8% and adjusted EPS fell 3.6% year on year. The planned reversal of customer orders placed ahead of the ERP cutover accounted for a 630-basis-point drag on organic growth, making near-term results volatile. (Solventum)
Results were weak outside advanced wound care: Dental Solutions’ third-quarter organic sales fell 7.4%, while Infection Prevention and Surgical Solutions fell 5.7%. That points to uneven demand across important parts of the portfolio, even allowing for ERP-related timing effects. (Solventum)
Management expects separating Health Information Systems to dilute annualised net operating margin by about 400 basis points. That drag could weigh on profitability as Solventum reshapes its portfolio, even if the separation sharpens the remaining business’s focus. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
SOLV Financial Performance
Revenues and expenses
SOLV Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing SOLV
AllUSDEURGBP
Fund name | Fund size | $SOLV weighting |
|---|---|---|
Invesco Health Care S&P US Select Sector$XLVS | $552M | 0.20% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 0.20% |
Xtrackers S&P 500 Equal Weight£XDWE | $16B | 0.19% |
Xtrackers S&P 500 Equal Weight$XDEW | $16B | 0.19% |
iShares S&P 500 Equal Weight$EWSX | $5.1B | 0.19% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.